Blepharitis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Blepharitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Blepharitis: Overview
Blepharitis is a common eye condition that makes your eyelids red, swollen, irritated, and itchy. It can cause crusty dandruff-like flakes on your eyelashes. Blepharitis can be uncomfortable. But it isn’t contagious, and it usually doesn’t cause any lasting damage to your eyes. The main treatment for blepharitis is regularly cleaning your eyelids and keeping them free of crusts. Blepharitis usually doesn’t go away completely, but you can take steps to manage your symptoms. Talk to your eye doctor about what’s causing your blepharitis and the best ways to manage it.
'Blepharitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blepharitis pipeline landscape is provided which includes the disease overview and Blepharitis treatment guidelines. The assessment part of the report embraces, in depth Blepharitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blepharitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Blepharitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Blepharitis Emerging Drugs
Further product details are provided in the report……..
Blepharitis: Therapeutic Assessment
This segment of the report provides insights about the different Blepharitis drugs segregated based on following parameters that define the scope of the report, such as:
Blepharitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blepharitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blepharitis drugs.
Blepharitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Blepharitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Blepharitis: Overview
Blepharitis is a common eye condition that makes your eyelids red, swollen, irritated, and itchy. It can cause crusty dandruff-like flakes on your eyelashes. Blepharitis can be uncomfortable. But it isn’t contagious, and it usually doesn’t cause any lasting damage to your eyes. The main treatment for blepharitis is regularly cleaning your eyelids and keeping them free of crusts. Blepharitis usually doesn’t go away completely, but you can take steps to manage your symptoms. Talk to your eye doctor about what’s causing your blepharitis and the best ways to manage it.
'Blepharitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blepharitis pipeline landscape is provided which includes the disease overview and Blepharitis treatment guidelines. The assessment part of the report embraces, in depth Blepharitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blepharitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Blepharitis R&D. The therapies under development are focused on novel approaches to treat/improve Blepharitis.
This segment of the Blepharitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Blepharitis Emerging Drugs
- NCX 4251: NicOx
- TP-03: Tarsus Pharmaceuticals,
Further product details are provided in the report……..
Blepharitis: Therapeutic Assessment
This segment of the report provides insights about the different Blepharitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Blepharitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Blepharitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blepharitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blepharitis drugs.
Blepharitis Report Insights
- Blepharitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Blepharitis drugs?
- How many Blepharitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blepharitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Blepharitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Blepharitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- NicOx
- Tarsus Pharmaceuticals
- AxeroVision
- InSite Vision
- NCX 4251
- TP-03
- AXR-270
- ISV-305
Introduction
Executive Summary
Blepharitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Blepharitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Blepharitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Blepharitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TP-03: Tarsus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NCX 4251: NicOx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Blepharitis Key Companies
Blepharitis Key Products
Blepharitis- Unmet Needs
Blepharitis- Market Drivers and Barriers
Blepharitis- Future Perspectives and Conclusion
Blepharitis Analyst Views
Blepharitis Key Companies
Appendix
Executive Summary
Blepharitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Blepharitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Blepharitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Blepharitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TP-03: Tarsus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
NCX 4251: NicOx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Blepharitis Key Companies
Blepharitis Key Products
Blepharitis- Unmet Needs
Blepharitis- Market Drivers and Barriers
Blepharitis- Future Perspectives and Conclusion
Blepharitis Analyst Views
Blepharitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Blepharitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Blepharitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Blepharitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Blepharitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products